

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

Personalised Medicine-Bringing Innovation to the Healthcare System

Collection Editors:

Dr. Denis Horgan

European Alliance for Personalized Medicine, Avenue de l'Armee/ Legerlaan 10, 1040 Brussels, Belgium

Prof. Dr. Gordon McVie

Institute of Molecular Oncology (IFOM) Milan, Cancer Studies, Kings College London, London, UK

Message from the Collection Editors

A major pillar in bringing new, targeted medicines to patients is, of course, innovation. This, in the realm of health, means the translation of knowledge and insight into what we can call 'value'. In addition, that value covers the value to patients, but also has to take into account value to healthcare systems, society and, of course, the manufacturers.

Of course, a personalised medicine approach is not always required. However, when it is, we should be working towards segmenting the use of even existing medicines (many of which do their job perfectly well) into responders and non-responders, which will in turn assist in the development of novel medicines.

On top of this, the technology now exists to apply the personalised medicine, genetic-based techniques in prevention, possibly via individual risk maps which may suggest specific guidance on living a healthy life.

All of this is built upon thorough research, of course. Which then needs to be translated via various process on the way to market, not least of which are regulatory approval and pricing.

This Project Collection deals with these areas.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us